Breast screening for women with a higher risk of breast cancer- Are we following the NICE guidelines?
Association of Breast Surgery ePoster Library. Tafazal H. 05/15/17; 166350; P110
Habib Tafazal
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction
NICE recommend that when setting up surveillance for women with a family history (FH) but no personal history of breast cancer we should “ensure that individual strategies are applied for women having mammographic surveillance”, that “surveillance is to NHSBSP standards” and “only undertaken after written information is given about risks and benefits”.
Methods
We retrospectively analysed prospectively collected data from all patients with a higher risk of breast cancer attending screening in our Trust (which operates over 3 sites), between 1st May 2014 and 27th May 2015. In particular we looked to see if we were adhering to the NICE guidelines outlined above. The audit standard was 100% compliance with each recommendation.
Results
We identified 447 patients attending for FH breast screening over the 13 month study period. 320 (72%) patients had a genetic assessment and an individually tailored screening plan. Screening was carried out according to NHSBSP standards on all 3 sites. However, we were disappointed but not surprised to see that no patients were given any written information regarding the specific risks and benefits of this screening programme.
Conclusion
With the continual expansion of genetic referrals, we are likely to see more young women at increased risk of breast cancer entering a prolonged breast screening programme. It is vital that these women are appropriately advised of the risks and benefits of this. We have designed a new patient information leaflet for these women which we believe will be of value to other Trusts in a similar position.
NICE recommend that when setting up surveillance for women with a family history (FH) but no personal history of breast cancer we should “ensure that individual strategies are applied for women having mammographic surveillance”, that “surveillance is to NHSBSP standards” and “only undertaken after written information is given about risks and benefits”.
Methods
We retrospectively analysed prospectively collected data from all patients with a higher risk of breast cancer attending screening in our Trust (which operates over 3 sites), between 1st May 2014 and 27th May 2015. In particular we looked to see if we were adhering to the NICE guidelines outlined above. The audit standard was 100% compliance with each recommendation.
Results
We identified 447 patients attending for FH breast screening over the 13 month study period. 320 (72%) patients had a genetic assessment and an individually tailored screening plan. Screening was carried out according to NHSBSP standards on all 3 sites. However, we were disappointed but not surprised to see that no patients were given any written information regarding the specific risks and benefits of this screening programme.
Conclusion
With the continual expansion of genetic referrals, we are likely to see more young women at increased risk of breast cancer entering a prolonged breast screening programme. It is vital that these women are appropriately advised of the risks and benefits of this. We have designed a new patient information leaflet for these women which we believe will be of value to other Trusts in a similar position.
Introduction
NICE recommend that when setting up surveillance for women with a family history (FH) but no personal history of breast cancer we should “ensure that individual strategies are applied for women having mammographic surveillance”, that “surveillance is to NHSBSP standards” and “only undertaken after written information is given about risks and benefits”.
Methods
We retrospectively analysed prospectively collected data from all patients with a higher risk of breast cancer attending screening in our Trust (which operates over 3 sites), between 1st May 2014 and 27th May 2015. In particular we looked to see if we were adhering to the NICE guidelines outlined above. The audit standard was 100% compliance with each recommendation.
Results
We identified 447 patients attending for FH breast screening over the 13 month study period. 320 (72%) patients had a genetic assessment and an individually tailored screening plan. Screening was carried out according to NHSBSP standards on all 3 sites. However, we were disappointed but not surprised to see that no patients were given any written information regarding the specific risks and benefits of this screening programme.
Conclusion
With the continual expansion of genetic referrals, we are likely to see more young women at increased risk of breast cancer entering a prolonged breast screening programme. It is vital that these women are appropriately advised of the risks and benefits of this. We have designed a new patient information leaflet for these women which we believe will be of value to other Trusts in a similar position.
NICE recommend that when setting up surveillance for women with a family history (FH) but no personal history of breast cancer we should “ensure that individual strategies are applied for women having mammographic surveillance”, that “surveillance is to NHSBSP standards” and “only undertaken after written information is given about risks and benefits”.
Methods
We retrospectively analysed prospectively collected data from all patients with a higher risk of breast cancer attending screening in our Trust (which operates over 3 sites), between 1st May 2014 and 27th May 2015. In particular we looked to see if we were adhering to the NICE guidelines outlined above. The audit standard was 100% compliance with each recommendation.
Results
We identified 447 patients attending for FH breast screening over the 13 month study period. 320 (72%) patients had a genetic assessment and an individually tailored screening plan. Screening was carried out according to NHSBSP standards on all 3 sites. However, we were disappointed but not surprised to see that no patients were given any written information regarding the specific risks and benefits of this screening programme.
Conclusion
With the continual expansion of genetic referrals, we are likely to see more young women at increased risk of breast cancer entering a prolonged breast screening programme. It is vital that these women are appropriately advised of the risks and benefits of this. We have designed a new patient information leaflet for these women which we believe will be of value to other Trusts in a similar position.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}